Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,343 result(s) found. Displaying page 1,278 of 2,218.
    «« First « Previous 1274  1275  1276  1277  1278  1279  1280  1281  1282  Next» Last»»
    EudraCT Number: 2009-013378-42 Sponsor Protocol Number: EBV09/01 Start Date*: 2010-10-08
    Sponsor Name:OM PHARMA SA
    Full Title: Double-blind, placebo-controlled, randomised clinical study of Broncho-Vaxom® drops in children suffering from recurrent Respiratory Tract Infections (RTIs)
    Medical condition: Recurrent respiratory tract infections
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10038133 Recurrent respiratory tract infections LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) HU (Completed) IT (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2010-018668-18 Sponsor Protocol Number: CCD-0916-PR-0032 Start Date*: 2010-06-22
    Sponsor Name:Chiesi Farmaceutici S.p.A.
    Full Title: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSS-OVER STUDY TO INVESTIGATE THE BRONCHODILATOR EFFICACY AND SAFETY AFTER SINGLE AND REPEATED ADMINISTRATIONS OF DIFFERENT DOSES OF GLYCOPYRROLATE V...
    Medical condition: COPD
    Disease: Version SOC Term Classification Code Term Level
    12.1 10010952 COPD LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-004333-34 Sponsor Protocol Number: EORTC 55041 Start Date*: 2005-09-20
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: A randomized, multicentre, phase III study of Erlotinib versus observation in patients with no evidence of disease progression after first line, platinum-based chemotherapy for high-risk Stage I an...
    Medical condition: Histologically confirmed high-risk FIGO stage I (grade 3, or aneuploid grade 1 or 2, or clear cell), or Stages II-IV ovarian epithelial, primary peritoneal, and fallopian tube cancer.
    Disease: Version SOC Term Classification Code Term Level
    8.0 10033283 HLGT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) ES (Completed) IT (Completed) AT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-000452-27 Sponsor Protocol Number: RABGRD1003 Start Date*: 2008-05-16
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Pharmacokinetic, Pharmacodynamic and Safety Study of Single and Multiple Doses of Rabeprazole in Pediatric Subjects with GERD 1 to 11 Months old, Inclusive
    Medical condition: Pediatric subjects with GERD
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018203 GERD LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-016243-20 Sponsor Protocol Number: 1245.20 Start Date*: 2010-10-26
    Sponsor Name:SCS Boehringer Ingelheim Comm.V
    Full Title: A phase III randomised, double-blind, placebo-controlled parallel group efficacy and safety study of BI 10773 and sitagliptin administered orally over 24 weeks, in drug naïve patients with type 2 d...
    Medical condition: Patients with type 2 diabetes mellitus.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022991-29 Sponsor Protocol Number: SMR/0211OBD-1033 Start Date*: 2011-02-01
    Sponsor Name:Sucampo Pharma Americas, Inc.
    Full Title: A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Patients with Opioid-induced Bowel Dysfunction
    Medical condition: Opioid-induced Bowel Dysfunction
    Disease: Version SOC Term Classification Code Term Level
    14.0 10017947 - Gastrointestinal disorders 10061247 Intestinal functional disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) BE (Completed) SE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2006-003772-35 Sponsor Protocol Number: AURA-6202-006 Start Date*: 2007-09-09
    Sponsor Name:Nerviano Medical Sciences S.r.l.
    Full Title: Phase II study of PHA-739358 administered by a 24-hour IV infusion every 14 days in advanced/metastatic breast, ovarian, colorectal, pancreatic, small cell lung and non small cell lung cancers.
    Medical condition: Advanced/metastatic breast, ovarian, colorectal, pancreatic, small cell lung, non small cell lung and squamous non small cell lung cancers.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059514 Small cell lung cancer metastatic PT
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033610 Pancreatic carcinoma metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) IT (Completed) FR (Completed) NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-005576-26 Sponsor Protocol Number: 08-PIR-04 Start Date*: 2009-02-19
    Sponsor Name:Nektar Therapeutics
    Full Title: A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) When Given on a Q14 Day or a Q21 Day Schedule in Patients with Metastatic or Unresectable L...
    Medical condition: Metastatic or Unresectable Locally Advanced Platinum-Resistant Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-019283-36 Sponsor Protocol Number: AC-058A201 Start Date*: 2010-08-05
    Sponsor Name:ACTELION Pharmaceuticals Ltd
    Full Title: A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety and tolerability of two doses of ACT-128800, an oral S1P1 receptor agonist, admini...
    Medical condition: Moderate to severe chronic plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10037153 Psoriasis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed) HU (Completed) BE (Completed) IT (Completed) AT (Completed) DK (Completed) GB (Completed) ES (Prematurely Ended) SE (Completed) BG (Completed) LT (Completed) LV (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2005-004272-20 Sponsor Protocol Number: E7389-E044-207 Start Date*: 2006-10-23
    Sponsor Name:Eisai Limited
    Full Title: Phase II Study of E7389 Administered as an IV Infusion Day 1 and 8 every 3 Weeks in Pretreated Patients with Advanced and/or Metastatic Soft Tissue Sarcoma Protocol Version 5.0 (2010-01-27)
    Medical condition: Advanced and/or metastatic soft tissue sarcoma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10041299 Soft tissue sarcomas HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) DK (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-021490-37 Sponsor Protocol Number: V419-007 Start Date*: 2011-03-09
    Sponsor Name:Sanofi Pasteur MSD
    Full Title: A Phase III Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4, and 12 Months.
    Medical condition: PR5I is developed to provide active immunization against diphtheria, tetanus, pertussis, poliomyelitis (caused by poliovirus Types 1, 2 and 3), invasive disease caused by Haemophilus influenza type...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10054130 Hepatitis B immunisation PT
    14.1 10042613 - Surgical and medical procedures 10054129 Diphtheria immunisation PT
    14.1 10042613 - Surgical and medical procedures 10053386 Poliomyelitis vaccine LLT
    14.1 10042613 - Surgical and medical procedures 10069543 Hemophilus influenzae type b immunization LLT
    14.1 10042613 - Surgical and medical procedures 10069577 Pertussis immunisation PT
    14.1 10021881 - Infections and infestations 10019731 Hepatitis B PT
    14.1 10042613 - Surgical and medical procedures 10054131 Tetanus immunisation PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) FI (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-011305-17 Sponsor Protocol Number: CA046 Start Date*: 2011-08-18
    Sponsor Name:Abraxis BioScience, LLC, a wholly-owned subsidiary of Celgene Corporation
    Full Title: A Randomized Phase III Study of Weekly ABI-007 plus Gemcitabine versus Gemcitabine Alone in Patients with Metastatic Adenocarcinoma of the Pancreas
    Medical condition: Metastatic Adenocarcinoma of the Pancreas
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10033599 Pancreatic adenocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Completed) BE (Completed) AT (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-023383-40 Sponsor Protocol Number: TB-402-006 Start Date*: 2011-02-15
    Sponsor Name:ThromboGenics N.V
    Full Title: Single Intravenous Administration of TB-402 for the Prophylaxis of Venous Thromboembolic Events (VTE) After Total Hip Replacement Surgery: A Phase IIb, Multicentre, Randomised, Active-Controlled, D...
    Medical condition: Venous Thromboembolic Event
    Disease: Version SOC Term Classification Code Term Level
    14.0 10042613 - Surgical and medical procedures 10049909 Venous thromboembolism prophylaxis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) LV (Completed) HU (Completed) AT (Completed) BG (Completed) NL (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2008-007997-39 Sponsor Protocol Number: B1831004(3082B2-4432-WW) Start Date*: 2009-04-09
    Sponsor Name:Wyeth Pharmaceuticals, Inc. Acting through its division Wyeth Research, a Pfizer Company
    Full Title: A Postauthorization Safety Surveillance Study of Patients Switching to ReFacto AF From ReFacto or Other Factor VIII Products in Usual Care Settings
    Medical condition: Severe haemophilia A (FVIII:C <1%) in male patients ≥12 years of age with a treatment history of >150 EDs to prior recombinant or plasma-derived FVIII replacement products and transitioning to ReFa...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10018937 Haemophilia A LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) BE (Completed) ES (Completed) SE (Completed) AT (Completed) FI (Completed) DK (Completed) FR (Completed) IT (Completed) PT (Prematurely Ended) NL (Completed) GB (Completed) CZ (Completed) GR (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2009-013056-71 Sponsor Protocol Number: TC-2402-038-SP Start Date*: 2010-03-10
    Sponsor Name:Takeda Pharma A/S
    Full Title: TachoSil versus current practice in dura sealing techniques for the prevention of post-operative cerebrospinal fluid (CSF) leaks in patients undergoing skull base surgery: An open label, randomised...
    Medical condition: Skull base surgery for the prevention of postoperative cerebrospinal fluid (CSF) leaks
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10067908 Neurosurgery PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) FI (Prematurely Ended) SE (Completed) DE (Completed) NL (Completed) GR (Completed) ES (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-013648-35 Sponsor Protocol Number: PENTA 18 Start Date*: 2010-06-23
    Sponsor Name:PENTA Foundation
    Full Title: KONCERT A Kaletra ONCE daily Randomised Trial of the pharmacokinetics, safety and efficacy of twice-daily versus once-daily lopinavir/ritonavir tablets dosed by weight as part of combination antir...
    Medical condition: Paediatric HIV-1 Infection
    Disease: Version SOC Term Classification Code Term Level
    12 10021881 HIV-1 Infection SOC
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IE (Completed) NL (Ongoing) FR (Completed) GB (Completed) ES (Completed) PT (Completed) BE (Completed) DE (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2007-001675-11 Sponsor Protocol Number: 0468E5-4439-WW Start Date*: 2008-02-27
    Sponsor Name:Wyeth Pharmaceuticals
    Full Title: A Randomised, Placebo Controlled, Double-Blinded Comparative Study Evaluating the Effect of Ramipril on Urinary Protein Excretion in Maintenance Renal Translplant Patients Converted to Sirolimus
    Medical condition: Prophylaxis of organ rejection in renal allograft recipients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050436 Prophylaxis against renal transplant rejection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed) BE (Completed) AT (Completed) DE (Completed) IT (Prematurely Ended) HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-019859-21 Sponsor Protocol Number: PMR-EC-1501 Start Date*: 2011-05-05
    Sponsor Name:Astellas Pharma Europe Ltd.
    Full Title: A Phase II, Open Label, Parallel Group, Multi-Center Study to Compare the Pharmacokinetics of Tacrolimus in Adult Subjects Undergoing Primary Allograft Transplantation Receiving an Advagraf® or Pro...
    Medical condition: Prophylaxis of primary heart, lung, pancreas, (including simultaneous pancreas kidney [SPK]) organ transplant rejection.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10050433 Prophylaxis against lung transplant rejection LLT
    12.1 10050432 Prophylaxis against heart transplant rejection LLT
    12.1 10050435 Prophylaxis against pancreas transplant rejection LLT
    12.1 10050438 Prophylaxis against renal and pancreas transplant rejection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed) GB (Completed) IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022383-12 Sponsor Protocol Number: CCX114157 Start Date*: 2011-02-16
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A 52 week Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Maintenance of Remission in Subjects with Crohn’s Disease
    Medical condition: Subjects with Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    16.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) DE (Completed) NO (Prematurely Ended) BE (Completed) SE (Prematurely Ended) GB (Prematurely Ended) DK (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) GR (Prematurely Ended) AT (Completed) ES (Prematurely Ended) PL (Prematurely Ended) PT (Prematurely Ended) EE (Prematurely Ended) IT (Completed) SK (Completed) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-019760-36 Sponsor Protocol Number: T05018-2004 Start Date*: 2010-11-22
    Sponsor Name:Grifols Therapeutics, Incorporated
    Full Title: A Phase 2, Randomized, Open-label (with Blinded Plasminogen Activator and Placebo Control Groups) Study to Evaluate the Effects of Different Intra-thrombus Infusion Regimens of Plasmin (Human) Comp...
    Medical condition: acute peripheral arterial occlusion
    Disease: Version SOC Term Classification Code Term Level
    14.0 10047065 - Vascular disorders 10057525 Peripheral artery occlusion LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) HU (Prematurely Ended) DE (Prematurely Ended) BE (Completed) ES (Prematurely Ended) CZ (Completed) BG (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 1274  1275  1276  1277  1278  1279  1280  1281  1282  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 14 18:40:05 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA